Synthetic Applications of the Parkins Nitrile Hydration Catalyst [PtH{(PMe2O)(2)H}(PMe2OH)]: A Review by Cadierno Menéndez, Victorio
Appl. Sci. 2015, 5, 380-401; doi:10.3390/app5030380 
 
applied sciences 
ISSN 2076-3417 
www.mdpi.com/journal/applsci 
Review 
Synthetic Applications of the Parkins Nitrile Hydration Catalyst 
[PtH{(PMe2O)2H}(PMe2OH)]: A Review 
Victorio Cadierno 
Laboratory of Organometallic Compounds and Catalysis (CSIC Associated Unit), Innovation Center in 
Advanced Chemistry (ORFEO-CINQA), Department of Organic and Inorganic Chemistry, Institute of 
Organometallic Chemistry “Enrique Moles”, Faculty of Chemistry, University of Oviedo,  
Oviedo E-33006, Spain; E-Mail: vcm@uniovi.es; Tel.: +34-985-103-453;  
Fax: +34-985-103-446. 
Academic Editor: Thomas J. J. Müller 
Received: 11 July 2015 / Accepted: 13 August 2015 / Published: 18 August 2015 
 
Abstract: The air-stable hydride-platinum(II) complex [PtH{(PMe2O)2H}(PMe2OH)], 
reported by Parkins and co-workers in 1995, is the most versatile catalyst currently available 
for the hydration of C≡N bonds. It features remarkable activity under relatively mild 
conditions and exceptionally high functional group compatibility, facts that have allowed the 
implementation of this complex in the synthesis of a large number of structurally complex, 
biologically active molecules and natural products. In this contribution, synthetic 
applications of the Parkins catalyst are reviewed. 
Keywords: homogeneous catalysis; hydration reactions; platinum; amides; nitriles;  
organic synthesis 
 
1. Introduction 
The selective transformation of a functional group within a complex molecule to generate target 
compounds is a very important issue in organic synthesis. Although this is not a trivial task, the use of 
homogeneous metal catalysts allows, in many cases, to reach compounds with remarkable levels of 
selectivity. Indeed, the field of homogeneous catalysis is currently so widespread that, in the literature, 
it is difficult to find advanced syntheses not using metal catalysts at some stage [1–3]. One of the organic 
transformations in which metal catalysts have played a key role is the hydration of nitriles (Scheme 1), 
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a process of great relevance in view of the broad industrial, synthetic, biological, and pharmacological 
applications of corresponding primary amide products [4–6]. 
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Scheme 1. The catalytic hydration of nitriles. 
The conversion of nitriles into amides by conventional acid/base strategies usually requires harsh 
conditions and remains impractical for most purposes due to yield and selectivity issues, since these 
classical methods are frequently unable to control the over-hydrolysis of the primary amide product [7,8]. 
The use of transition metal complexes (mainly of Groups 8–12) as catalysts under neutral and mild 
conditions has allowed researchers to overcome these traditional barriers, and a large number of selective 
catalysts for the nitrile hydration process have seen the light during the last two  
decades [9–15]. Among them, the commercially available hydride-platinum(II) complex 
[PtH{(PMe2O)2H}(PMe2OH)] (1), first described by Ghaffar and Parkins in 1995 [16,17], has achieved 
great success among organic chemists because of its outstanding activity and selectivity and its exquisite 
compatibility with other functional groups (Figure 1). As a matter of fact, this platinum complex has 
found applications in the synthesis of a huge number of natural products and biologically active 
molecules of elaborate structure, making it the most widely used catalyst to date for the hydration of 
C≡N bonds. 
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Figure 1. Structure of the nitrile hydration catalyst [PtH{(PMe2O)2H}(PMe2OH)] (1). 
This article intends to provide a comprehensive account on the chemistry and synthetic applications 
of [PtH{(PMe2O)2H}(PMe2OH)] (1). The literature and patented works published up to July 2015  
are covered. 
2. Preparation of Complex [PtH{(PMe2O)2H}(PMe2OH)], First Catalytic Studies and Mechanism 
of Action 
The synthesis of complex [PtH{(PMe2O)2H}(PMe2OH)] (1) involves the reaction of the platinum(0) 
precursor [Pt(PPh3)4] with an excess (five equiv.) of dimethylphosphine oxide Me2P(=O)H, which 
tautomerizes in situ into the phosphinite ligand Me2POH, in toluene under inert atmosphere. The reaction 
proceeds at room temperature, and the complex precipitates directly in the medium, thus making its 
isolation easy by simple filtration (isolated yields are usually in the range 75%–80%) [16–19]. In their 
first studies, Parkins and Ghaffar demonstrated the ability of 1 to selectively hydrate different model 
nitrile substrates, such as benzonitrile, acetonitrile, acrylonitrile, or 3-cyanopyridine, employing water, 
aqueous ethanol, or aqueous THF as the reaction medium at 70–90 °C [16–18]. The remarkable activity 
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of [PtH{(PMe2O)2H}(PMe2OH)] (1) was readily evidenced in these seminal works, with reported 
turnover frequencies exceeding 1400 h−1 and turnover numbers of up to 77,000. Remarkably, contrary 
to other metal catalysts reported in the literature, complex 1 was able to operate under neutral conditions. 
The studies by Parkins and Ghaffar also showed that the size of the substituents on the phosphorus ligand 
is key to achieving good catalytic activity, the performances of the related complex 
[PtH{(PPh2O)2H}(PPh2OH)] containing a bulkier phosphinito ligand being significantly lower in 
comparison to those of 1 (an additional example has been recently described [20]). Further evidence of 
the synthetic potential of complex [PtH{(PMe2O)2H}(PMe2OH)] (1) was given by de Vries and  
co-workers, who reported excellent yields and chemoselectivities in the hydration of a variety of 
sterically hindered tertiary nitriles and nitriles containing acid- or base-sensitive functional groups (some 
representative examples are shown in Figure 2) [21]. 
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Figure 2. Examples of nitriles that complex 1 is able to hydrate. 
Concerning its mechanism of action, Ghaffar and Parkins proposed that in aqueous medium, 
protonation of the hydride ligand of 1 by water readily takes place, generating a vacant coordination site 
on the metal for substrate binding, with concomitant dihydrogen extrusion (Scheme 2) [16–18]. 
 
Scheme 2. Proposed mechanism for the catalytic hydration of nitriles with complex 1. 
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Then, an intramolecular nucleophilic attack of the OH group of the PMe2OH ligand on the 
coordinated nitrile takes place, affording the five-membered metallacyclic intermediate A. Further 
hydrolysis of this metallacycle generates the amide product and regenerates the active platinum  
species [16–18]. 
3. Application of Complex [PtH{(PMe2O)2H}(PMe2OH)] in the Total Synthesis of  
Natural Products 
Capuramycin (5), a nucleoside antibiotic isolated from the culture filtrate of Streptomyces griseus 
446-S3 [22], and its congeners are considered to be important lead molecules for the development of 
new drugs for Mycobacterium tuberculosis infections [23]. Accordingly, remarkable efforts have been 
devoted to establish convergent synthetic routes to access 5 that allow the preparation of analogues for 
SAR (structure-activity relationship) studies [24]. In this context, in 2009, Kurosu and co-workers 
described a concise synthesis of capuramycin (5), starting from the partially protected uridine 2  
(15 steps), in which the primary amide unit was conveniently generated by the hydration of the C≡N 
unit of intermediate 3 using [PtH{(PMe2O)2H}(PMe2OH)] (1) (Scheme 3) [25]. The hydration reaction, 
performed in aqueous ethanol at 70 °C, with 5 mol% of 1, allowed the quantitative conversion of 3 to 
the corresponding amide 4. 
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Scheme 3. The Parkins catalyst in the synthesis of capuramycin. 
(−)-Huperzine A (9) is a tricyclic alkaloid produced by the Chinese herb Hupercia serrata [26], with 
intense contemporary interest in clinical application for treating neurodegenerative diseases [27–29]. 
Several total syntheses of 9 have been reported [27–29]. In one of the most recent and scalable (eight 
steps starting from (R)-4-methyl-cyclohex-2-ene-1-one (6); 35%–45% overall yield), complex 1 was 
employed to promote the high-yield conversion of advanced nitrile intermediate 7 into amide 8 in 
aqueous ethanol (Scheme 4) [30]. From 8, Hoffmann's rearrangement of the amide group by means of 
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[bis(trifluoroacetoxy)iodo]benzene (PIFA), followed by in situ deprotection of the pyridone unit with 
iodotrimethylsilane (TMSI), delivered the desired alkaloid. 
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Scheme 4. The Parkins catalyst in the synthesis of (−)-huperzine A. 
The selective hydration of nitrile 10 to generate primary amide 11, an advanced intermediate for the 
Nicolaou’s synthesis of the marine natural product diazonamide A (12) [31,32], using 
[PtH{(PMe2O)2H}(PMe2OH)] (1) was described by Sammakia and co-workers (Scheme 5) [33]. The 
reaction proceeded cleanly in aqueous ethanol at 120 °C with a catalyst loading of only 2 mol%, 
delivering 11 in 92% isolated yield. 
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Scheme 5. Synthesis of an amide intermediate for the preparation of diazonamide A. 
The welwitindolinones are a fascinating group of structurally unique metabolites isolated from  
blue-green algae that contain 3,4-bridged or spiro-cyclobutaneoxindole moieties [34,35]. Due to their 
challenging structures and their broad spectrum of biological activities, these compounds have attracted 
the attention of synthetic chemists for some time, although their complexity has prevented the 
completion of total syntheses for most of them thus far [36]. In an approach to welwitindolinone C 
isothiocyanate (welwistatin 17), Funk and co-workers have described the preparation of the related 
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indole isocyanate derivative 16 starting from the vinylcyclohexanone 13 after 13 steps (Scheme 6) [37]. 
In this synthesis, the Parkins catalyst was employed to hydrate the encumbered nitrile 14. A high loading 
of complex 1 (42 mol%) was, in this case, required to generate the bridgehead primary amide 15 in high 
yield (73%). In the presence of Pb(OAc)4, amide 15 evolved into the final isocyanate 16 through the 
Baumgarten variant of the Hoffmann rearrangement. 
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Scheme 6. Funk’s approach to the synthesis of welwistatin. 
In 2009, Jones and Krische developed a total synthesis of (+)-geniposide (21), an iridoid  
β-glucoside of natural origin with anti-tumor and anti-inflammatory activity, starting from  
pivalate-protected lactol 18 (Scheme 7) [38]. During this synthesis the conversion of nitrile intermediate 
19 into amide 20 was successfully accomplished in 87% yield using 20 mol% of the platinum complex 
[PtH{(PMe2O)2H}(PMe2OH)] (1). 
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Scheme 7. The hydration step in total synthesis of (+)-geniposide. 
SB-203207 (25), an alkaloid isolated from a Streptomices species by researchers in the SmithKline 
Beecham group, was found to show marked isoleucyl tRNA synthetase inhibition activity [39,40]. Very 
recently, Kan and co-workers described a total synthesis of this compound starting from lactam 22, in 
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which the primary amide unit was generated by catalytic hydration of nitrile intermediate 23 with 
complex 1 (Scheme 8) [41]. As in the two previous cases, a high loading of 1 was needed to obtain the 
corresponding amide product 24 in high yield. SB-203207 can also be accessed by acylation of the 
sulfonamide unit of naturally occurring altemicidin (26 in Scheme 8) [42]. In this context, the 
stereoselective synthesis of a key intermediate for altemicidin, i.e. amide 27 (see Scheme 8), was 
accomplished by Kan and Fukuyama employing [PtH{(PMe2O)2H}(PMe2OH)] (1) [43]. Compound 27 
was obtained in quantitative yield by the hydration of the corresponding nitrile in aqueous ethanol at  
75 °C for 12 h with 28 mol% of 1. 
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Scheme 8. The Parkins catalyst in the synthesis of alkaloid SB-203207. 
In a synthetic approach toward the cytotoxic indole alkaloid avrainvillamide (30) and its dimeric form 
stephacidin B (31) [44], Myers and co-workers used [PtH{(PMe2O)2H}(PMe2OH)] (1) to synthesize 
primary amide intermediate 29 by the hydration of nitrile 28 (Scheme 9) [45,46]. The reaction proceeded 
cleanly in aqueous ethanol at 70 °C and with 20 mol% of 1, affording 29 in 85% isolated yield. 
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Scheme 9. The Parkins catalyst in the synthesis of avrainvillamide and stephacidin B. 
The manzacidins are a family of marine natural products featuring a tetrahydropyrimidine carboxylic 
acid and an ester-linked bromopyrrole unit. This class of alkaloids has attracted significant attention due 
to their biological activities and unusual structure. Consequently, many groups have described the 
enantio- and diastereoselective synthesis of some of them [47]. In this context, Deng and co-workers 
reported synthetic routes to manzacidin A (34) [48,49] and manzacidin C (37) [50] involving a nitrile 
hydration step promoted by complex [PtH{(PMe2O)2H}(PMe2OH)] (1) (Scheme 10). In particular, 1 
was used to transform the diasteromeric nitriles 32 and 35 into the corresponding primary amide 
intermediates 33 and 36, respectively. As shown in the scheme, almost quantitative yields were achieved 
in both cases, performing the reactions at 80 °C with low catalyst loading (5 mol%). 
EtOH / H2O (19:1)
 80 ºC / 8.5 h
(97% yield)
1 (5 mol%)
32
TBDPS = tert-butyldiphenylsilyl
CN
TBDPSO OTBDPS
N3 C
TBDPSO OTBDPS
N3
OH2N
33
7 steps HN N
CO2H
O
O
N
H
Br
34
manzacidin A
EtOH / H2O (19:1)
 80 ºC / 10 h
(97% yield)
1 (5 mol%)
35
CN
OTBDPS
N3 C
OTBDPS
N3
OH2N
36
7 steps HN N
CO2H
O
O
N
H
Br
37
manzacidin C
TBDPSO TBDPSO
 
Scheme 10. Hydration steps in the syntheses of manzacidins developed by Deng. 
In the context of their synthetic studies on the icetaxane family of diterpenoids, the hydration of nitrile 
38 by complex 1 was successfully employed by Sarpong and co-workers to prepare primary amide 39, 
from which the formal synthesis of icetexone (40) and epi-icetexone (41) could be completed  
(Scheme 11) [51,52]. 
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Scheme 11. Structure of icetexone and epi-icetexone, and synthesis of one intermediate. 
The marine natural product psymberin (42 in Figure 3) has attracted a great deal of attention since its 
discovery in 2004 due to its complex architecture, biological properties, and paucity in nature. This 
interest has resulted in a large number of synthetic investigations and the development of analogous 
molecules [53]. The Parkins catalyst [PtH{(PMe2O)2H}(PMe2OH)] (1) has been involved in some of 
these studies [54–59]. In particular, in the first total synthesis of this compound, De Brabender and  
co-workers employed 1 to synthesize advanced amide intermediate 43 from the corresponding  
nitrile [54,55,57]. The same group also described the synthesis of different psymberin analogues from 
primary amide 44, which was also accessed though a nitrile hydration reaction promoted by 1 [56,57]. 
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Figure 3. Structure of psymberin and amides 43–44. 
The total syntheses of the prenylated indole alkaloids citrinalin B (47) and cyclopiamine (48) has 
been recently accomplished for the first time by Mercado-Marin, García-Reinada, and co-workers 
(Scheme 12) [60]. In their work, the key carbamate intermediate 46 was generated through a two-step 
sequence from tricyclic nitrile 45 via initial hydration of the C≡N catalyzed by complex 
[PtH{(PMe2O)2H}(PMe2OH)] (1), followed by Hofmann rearrangement of the resulting carboxamide 
(not isolated) promoted by PIFA in MeOH. 
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Scheme 12. The Parkins catalyst in the total synthesis of citrinalin B and cyclopiamine B. 
In an independent work, Sarpong and co-workers reported the preparation of the related  
17-hydroxy-citrinalin B (50), as well as those of the alkaloids stephacidin A (51) and notoamide I (52), 
using carbamate 49 as a common intermediate (Figure 4) [61]. As in the previous case, formation of 49 
was accomplished through a hydration/Hofmann rearrangement sequence from the corresponding nitrile, 
the hydration step being again promoted by the Parkins platinum catalyst 1. 
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Figure 4. Structure of the carbamate 49 and the alkaloids 50–52. 
Finally, Fleming and co-workers reported the preparation of a series of morinol-type lignans 55 
starting from α,β-unsaturated nitriles 53 (Scheme 13) [62]. The selective transformation of the 
alkenenitrile unit of 53 into the allylic alcohol one involved an initial hydration step, catalyzed by 
complex [PtH{(PMe2O)2H}(PMe2OH)] (1), followed by an acylation/reduction of the resulting  
amides 54. 
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Scheme 13. Synthetic route to morinol-type lignans. 
4. Application of Complex [PtH{(PMe2O)2H}(PMe2OH)] in the Synthesis of Other Biologically 
Active Molecules and Pharmaceutical Compounds 
One of the first synthetic applications of complex [PtH{(PMe2O)2H}(PMe2OH)] (1) was in the 
preparation of atenolol (57), a drug belonging to the group of β-blockers which contains a primary amide 
group and is commonly employed in the treatment of hypertension [63]. In particular, 1 had no difficulty 
in promoting the final hydration step of the nitrile intermediate 56. Thus, as shown in Scheme 14, 
performing the reaction in a refluxing ethanol/water (1:1 v/v) mixture, and using a very low catalyst 
loading of 0.0001 mol%, atenolol could be selectively obtained in 93% yield [64]. 
EtOH / H2O (1:1)
reflux / 72 h
(93% yield)
1 (0.0001 mol%)
56
OH
CN
O
CN
O
O
CN
OH
NHiPr
57
O
C
OH
NHiPr
NH2
O
atenolol
MeOH / r.t.
iPrNH2Cl
O
piperidine
100 ºC
 
Scheme 14. Application of the Parkins catalyst in the synthesis of atenolol. 
The steroidal compound eplerenone (60) is an orally-active aldosterone antagonist featuring a 
canrenone-type structure that is also used for the treatment of hypertension and heart failure [65,66]. The 
synthesis of 60 has been the subject of several patents. In one of them, the Parkins catalyst was 
successfully employed to transform the advanced intermediate 7α-cyano-9(11)Δ-canrenone 58 into  
7α-carbamoyl-9(11)Δ-canrenone 59 (Scheme 15) [67]. Conversion of the amide unit of 59 to the 
corresponding carboxylic acid, followed by esterification, or direct alcoholysis of the amide to the ester, 
completed the synthesis of 60. 
Antagonists of the kappa opioid receptor have great therapeutic potential for the treatment of a range 
of central nervous system diseases and disorders, including, for example, schizophrenia, depression, and 
anxiety [68–70]. Quite recently, 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides, as exemplified by 61 in 
Figure 5, were identified by Brugel and co-workers as potent and selective kappa opioid receptor 
antagonists [71]. In an additional SAR study, the same authors synthesized a large number of related 
compounds, such as 62 and 63, in which the benzamide unit was generated by hydration of the 
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corresponding nitrile with the Parkins catalyst [72]. Reactions were performed in an EtOH/water  
(6:1 v/v) mixture at 80 °C, but no details on the yields, metal loadings, and reaction times were given in 
the document. The preparation of the structurally related azabicyclooctane derivatives 64 using 1 was 
also described, and their receptor binding affinity for kappa, mu, and delta opioid receptors was 
evaluated [73]. 
1 (1 mol%)
O
O
O
O
OMe
O
60
O
O
O
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O
O
O
O
NH2
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EtOH / H2O (15:1)
70 ºC / 16 h
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Scheme 15. The Parkins catalyst in the synthesis of the aldosterone antagonist eplerenone. 
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Figure 5. Structure of the opioid receptor antagonists 61-64. 
In a patented work directed to the identification of novel histamine H3 receptor ligands, Brugel and 
co-workers also employed complex [PtH{(PMe2O)2H}(PMe2OH)] (1) to promote the high yield 
conversion of the racemic cyclopropyl-substituted benzamide 65 into primary amide 66  
(Scheme 16) [74]. It is of note that when the same reaction was carried out employing an excess of KOH 
as the promoter, 66 was obtained in a much lower yield (69% vs. 97%). 
1 (23 mol%)
NC
65
EtOH / H2O (5:1)
70 ºC / 3 h
(97% yield)
O
N
N
C
66
O
N
N
O
NH2  
Scheme 16. Catalytic synthesis of a cyclopropyl-substituted benzamide using 1. 
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In addition, hydration with the Parkins catalyst 1 was also successfully employed to transform the 
acetate- and pivaloate-protected aminonitrile glycoside 67 and the morphinan derivative 69 into the 
corresponding primary amides 68 and 70, respectively (Scheme 17) [75,76]. 
1 (2 mol%)
67
EtOH / H2O (4:1)
70 ºC / 7 h
(55-98% yield)
O
RO
RO
RO
RO
BnN
CN
O
O
RO
RO
RO
RO
BnN
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N
O
C
H
N
70
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Scheme 17. Catalytic hydration of the biologically active nitriles 67 and 69. 
5. Other Synthetic Applications of Complex [PtH{(PMe2O)2H}(PMe2OH)] 
The synthetic utility of the Parkins catalyst [PtH{(PMe2O)2H}(PMe2OH)] (1) is not restricted to the 
catalytic hydration of nitriles. Using this complex, other amide-bond forming reactions could be 
developed. In this context, de Vries and co-workers found that 1 efficiently catalyzes the direct 
conversion of unactivated nitriles to N-substituted amides by reaction with both primary and secondary 
amines in the presence of water (Scheme 18) [77]. A mechanism involving the initial formation of an 
amidine intermediate, which subsequently hydrolyzes into the amide, was proposed. Indeed, when the 
reactions were performed in the absence of water, the corresponding amidines could be isolated. 
1 (0.1 mol%)
DME / 160 ºC / 18-70 h
(51-89% yield)
R2R3NH= PhNH2, nPrNH2, BnNH2, Pyrrolidine, Piperidine, Morpholine
R1CN = MeCN, PhCN, n-C6H13CN (not all combinations)
R1
O
NR2R3
+   NH3+  R2R3NH  +  H2OR1 N
R1
NH
NR2R3
 
Scheme 18. Hydrolytic amidation of nitriles catalyzed by [PtH{(PMe2O)2H}(PMe2OH)] (1). 
An interesting extension of this amidation process is the quantitative formation of  
2-ethyl-2-oxazoline 72 from the reaction of propionitrile with 2-aminoethanol via ring-closure  
of the intermediate amidine 71 (Scheme 19) [77]. 
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1 (0.1 mol%)
DME / 160 ºC
+   NH3+N
NH
N
H
NH2
HO O
N
72
OH
71  
Scheme 19. Catalytic synthesis of 2-ethyl-2-oxazoline. 
Although scarcely explored, the ability of complex 1 to promote the hydration of thiocyanates was 
also demonstrated [78,79]. As a representative example, treatment of the optically active thiocyanate 73 
with 25 mol% of 1 in a THF/H2O mixture led to the high-yield formation of thiocarbamate 74  
(Scheme 20). Remarkably, in marked contrast with the use of classical acidic hydrolysis conditions, 
which induced the complete racemization at the stereogenic carbonyl α-carbon, the reaction proceeded 
without loss of chirality. 
1 (25 mol%)
73
THF / H2O (2:1)
40 ºC / 2 h
(92% yield)
MeO
N
O
O
O
Ph
NCS
74
MeO
N
O
O
O
Ph
SH2N
O
 
Scheme 20. Catalytic hydration of an optically active thiocyanate. 
On the other hand, in the presence of catalytic amounts of [PtH{(PMe2O)2H}(PMe2OH)] (1), 
separable mixtures of 1-ethoxyisoquinolines 76 and isoquinolones 77 were synthesized by 
intramolecular 6-endo-dig cyclization of ortho-alkynylbenzonitriles 75 in ethanol (Scheme 21) [80]. In 
these reactions the Parkins catalyst activates not only the nitrile unit, but also the alkyne moiety of the 
substrates. The use of other alcohols, such as methanol, iso-propanol, or cyclopentanol, also led to 
mixtures of the corresponding 1-alkoxyisoquinolines and isoquinolones 77. 
1 (10 mol%)
EtOH / reflux / 16-48 h
(16-49% yield)
75
N
R1
R2 R2
N
OEt
R1
76
+ R2
NH
O
R1
77
(5-19% yield)
R2 = H; R1 = Ph, 4-C6H4OMe, 4-C6H4F, 3-Pyridyl, 3-Thienyl, Cy
R2 = 3-F, 5-CF3, 5-OMe, 4-Me; R1 = Ph  
Scheme 21. Platinum-catalyzed intramolecular cyclization of ortho-alkynylbenzonitriles. 
In an independent patented work, a more selective transformation of ortho-alkynylbenzonitrile 78 
was observed [81]. Thus, as shown in Scheme 22, the treatment of this substrate with 2 mol% of platinum 
complex 1 in refluxing methanol resulted in the exclusive formation of isoquinolone 79. 
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1 (2 mol%)
EtOH / reflux / 2 h
78
N
NH
O
79
(81% yield)
MeO2SHN
OMe
Br
tBu
MeO2SHN OMe
Br
tBu
 
Scheme 22. Selective synthesis of isoquinolone 79 using complex 1. 
6. Limitations 
Despite the broad scope shown by complex [PtH{(PMe2O)2H}(PMe2OH)] (1), a major limitation was 
encountered when studying its application for the catalytic hydration of cyanohydrins, i.e.  
α-hydroxynitriles. Unfortunately, the hydration rates for these substrates were very low in comparison 
to those observed with other nitriles, and only a few turnovers could be achieved [82,83]. The poor 
reactivity observed was ascribed to the low stability of the cyanohydrin substrates, which slowly 
equilibrate in solution with HCN and the corresponding aldehyde or ketone (Scheme 23), and the 
irreversible coordination of the cyanide anion to platinum leads to the deactivation of the catalyst. In 
fact, most of the nitrile hydration catalysts reported to date are poisoned by cyanide and, therefore, with 
some notable exceptions [84–89], are inoperative with this particular class of nitriles. 
R R
O
+ C NH H C N+
R
C
OH
NR
 
Scheme 23. Equilibrium between a cyanohydrin and the corresponding aldehyde/ketone and 
hydrogen cyanide. 
Although with only one example, Parkins and co-workers showed that this limitation can be 
circumvented, protecting the OH group of the cyanohydrin prior to the hydration reaction [90]. Thus, as 
shown in Scheme 24, mandelamide (83) was accessible from mandelonitrile (80) by the hydration of the 
corresponding mixed acetal 81 and the subsequent removal of the α-butoxyethoxy protecting group in 
the resulting amide 82 with dilute acid. In this context, we must also stress that the ability of complex 1 
to promote the selective conversion of cyanohydrin acetates into α-acetoxy amides has also been 
demonstrated [91]. 
Ph
HO
N
Ph
O
N
OnBu
80 81
OnBu
H2SO4 / 0 ºC
(62% yield)
Ph
O
NH2
OnBu
82
1 (0.3 mol%)
(88% yield)
O
EtOH / H2O (2:1)
reflux / 46 h
Ph
HO
NH2
83
HCl(aq)
(42% yield)
O
r.t. / 1 h
 
Scheme 24. Access to mandelamide from mandelonitrile using the Parkins catalyst. 
In addition to cyanohydrins, other nitriles mentioned in the literature for which complex 
[PtH{(PMe2O)2H}(PMe2OH)] (1) proved ineffective were 84 and 85 (Figure 6). In the case of 84, the 
treatment with 1 in an EtOH/H2O mixture at 70 °C resulted in the decyanation of the substrate and 
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generation of the corresponding aldimine [92]. For the malonodinitrile 85, although its monohydration 
using 1 was possible, the reaction yield was very low in comparison to that achieved employing the more 
classical KF-Al2O3 system [93]. 
85
NC CN
N O
Bn
OBN
CN
NHPMB
N
PMB
84
PMB = p-methoxybenzyl
 
Figure 6. Structure of the nitriles 84 and 85. 
7. Conclusions 
In summary, in this paper we have tried to summarize, in a comprehensive manner, all the  
synthetic processes in which the commercially available phosphinito-platinum(II) complex 
[PtH{(PMe2O)2H}(PMe2OH)] (1) has been involved to date. Although tens of nitrile hydration  
catalysts are currently known, none has achieved nearly the same success of compex 1. From the 
examples shown along the manuscript, it is easy to realize the extraordinary synthetic usefulness of this 
complex, which is capable of promoting the selective hydration of C≡N units in densely functionalized 
molecules of very high structural complexity due to its exceptionally high functional group 
compatibility. The high synthetic versatility of the primary amide −C(=O)NH2 function, along with its 
presence in a multitude of natural products and biological active molecules already known, and certainly 
in many others waiting to be discovered, allow us to presume an increase in the use of 1 in the near 
future. In short, the Parkins catalyst [PtH{(PMe2O)2H}(PMe2OH)] (1) is called to occupy a preferred 
position within the toolbox of synthetic organic chemists. 
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